Connect with us

Technology

Valmet to supply the third Advantage DCT 200 tissue production line to Velvet CARE Paper Mill in Poland

Published

on

Valmet Oyj press release, July 9, 2024, at 9:30 a.m. EEST

ESPOO, Finland, July 9, 2024 /PRNewswire/ — Velvet CARE has decided to invest in a third Valmet Advantage DCT tissue line for its mill in Osada Klucze, Poland. The order includes an extensive automation package, a control valve package, and Industrial Internet solutions. The target is to meet consumers’ increasing demand for high-quality tissue products with low environmental impact.

The order is included in Valmet’s orders received of the second quarter 2024. The value of the order will not be disclosed.

Valmet and Velvet CARE have a strong history of cooperation, and Valmet has previously delivered two tissue lines to the same mill, starting up in 2018 and 2021.

Valmet’s Advantage DCT 200 tissue machine is equipped with the latest technology to ensure the highest product quality while reducing energy and water consumption and CO2 emissions. 

“We appreciate Valmet for being an indispensable partner in Velvet CARE’s success. The cutting-edge technology and unwavering support have elevated our operations, making Valmet an invaluable contributor to our industry leadership. We look forward to continued collaboration and shared success,” says Wanda Ciesielczuk, Vice President, Velvet CARE.

“It has been a pleasure to follow Velvet CARE from the start-up of their first Valmet machine. They pay attention to all details required to produce premium tissue with high efficiency, focusing on quality in all aspects. We are proud to be chosen again as their supplier and look forward to working together to make the new machine as successful as the previous two,” says Joakim Karas, Capital Sales Manager, Tissue Mills business unit, Paper business line, Valmet.

Delivery’s technical information

Valmet’s scope of supply comprises an Advantage DCT 200 tissue machine equipped with an OptiFlo headbox and a Yankee cylinder. The line will also feature Advantage tissue technology, including a ViscoNip press, an AirCap Advantage hood with an air system, WetDust systems, and a SoftReel reel.

Valmet will also deliver detailed mill engineering, full stock preparation equipment, a manual pulper feed system, and an automation package, including a Valmet DNA Distributed Control System (DCS) with built-in machine condition monitoring and a Valmet IQ Quality Control System (QCS). The delivery will include a control valve package with valve automation solutions. Valmet Tissue Performance Center services are also part of the scope.

The new tissue line will have a design speed of 2,200 m/min, a width of 5.6 meters, and an annual production capacity of 70,000 tons. It is optimized to save energy and deliver excellent paper properties.

About the customer

Velvet CARE is one of the largest and most modern producers of paper hygiene products in Poland and Central Europe. Its main production facility is in Klucze, southern Poland, with a commercial office in Warsaw. Established in 2013, the company carries over 100 years of heritage in papermaking, with the Klucze factory in operation since 1897. Velvet CARE’s current annual capacity is up to 150,000 tonnes, with products sold in approximately 30 countries.

VALMET 
Corporate Communications 

For further information, please contact:

Joakim Karas, Capital Sales Manager, Tissue Mills business unit, Paper business line, Valmet, tel. +46 703 684 232

Jenny Lahti-Samuelsson, VP Sales, Tissue Mills business unit, Paper business line, Valmet, tel. + 46 703 171 287

Valmet is a leading global developer and supplier of process technologies, automation and services for the pulp, paper and energy industries. With our automation systems and flow control solutions we serve an even wider base of process industries. Our more than 19,000 professionals around the world work close to our customers and are committed to moving our customers’ performance forward – every day.

The company has over 220 years of industrial history and a strong track record in continuous improvement and renewal. Valmet’s net sales in 2023 were approximately EUR 5.5 billion.

Valmet’s shares are listed on the Nasdaq Helsinki and the head office is in Espoo, Finland.   

Follow us on valmet.com | X | X (IR) | LinkedIn | Facebook | YouTube | Instagram |

Processing of personal data  

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/valmet-oyj/r/valmet-to-supply-the-third-advantage-dct-200-tissue-production-line-to-velvet-care-paper-mill-in-pol,c4012573

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/valmet-to-supply-the-third-advantage-dct-200-tissue-production-line-to-velvet-care-paper-mill-in-poland-302191688.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

TriNetX’s Founding CEO Announces Plans to Step Down

Published

on

By

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board

CAMBRIDGE, Mass., Jan. 9, 2025 /PRNewswire/ — TriNetX, the largest global source of real-world data, today announced that Gadi Lachman, the Company’s Founder, President and CEO, will step down from his operating role on March 31, 2025. Gadi founded TriNetX in 2014 and has served as President and CEO in the succeeding 11 years. Gadi will continue to serve on TriNetX’s Board of Directors and will be an Advisor to Carlyle, TriNetX’s majority investor.

“It has been an honor to build TriNetX and be part of such an outstanding team. I want to thank TriNetX’s employees, customers, and shareholders for the support they have shown me. With the talent and passion of our people I am immensely confident in TriNetX’s continued success,” said Lachman. “Together, we have built the largest global platform for clinical research, with data from over 25 countries and tens of millions of queries a month. Our solutions are moving clinical research to a whole different level and saving lives on a massive scale, across all therapeutic areas.”

During the transition period, Jeff Margolis, a current TriNetX Director, will serve as Executive Chairman to ensure continuity in leadership and governance while a CEO search is conducted.

Margolis said, “I have had the distinct privilege of serving on the Board alongside Gadi and partnering with him for 11 years. On behalf of the Board, we thank Gadi for shaping and leading TriNetX to become the world’s top ecosystem of real-world data and real-world evidence serving life sciences and the broader healthcare industry. I look forward to working with him and the rest of the Board over the next months to execute a successful transition of leadership.”

Joe Bress, Partner and Global Co-Head of Healthcare for Carlyle, TriNetX’s lead investor, added, “We have been thrilled to partner with Gadi since our initial investment in TriNetX over four years ago. Thanks to his disciplined leadership, TriNetX is one of the few companies that has sustained profitability even during periods of high growth. Gadi has built the company up to an exciting point, paving the way for a new leader to take the business into its next chapter of growth and success.”

Through this leadership transition, TriNetX remains steadfast in its mission to advance global healthcare through the power of real-world data. The Board, leadership team, and employees are united in their commitment to driving continued innovation and delivering success for customers and partners, all while building on Gadi’s exceptional legacy.

About TriNetX, LLC

TriNetX is a global network of healthcare organizations and life sciences companies dedicated to advancing real-world research and expediting the development of new therapies. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, please visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn.

Media Contact
TriNetX
Michelle Fleming, Chief Marketing Officer
Email: Michelle.Fleming@TriNetX.com

Logo – https://mma.prnewswire.com/media/542641/TriNetX_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/trinetxs-founding-ceo-announces-plans-to-step-down-302347367.html

Continue Reading

Technology

Stellus Private Credit BDC Announces $0.36 First Quarter 2025 Regular Dividend, Payable Monthly in Increments of $0.12 in January, February, and March 2025

Published

on

By

HOUSTON, Jan. 9, 2025 /PRNewswire/ — Stellus Private Credit BDC (“the Company”) announced that its Board of Trustees has declared a monthly dividend of $0.12 for each of January, February, and March, totaling $0.36 per share in the aggregate for the first quarter of 2025. The regular dividend of $0.36 per share will be paid to shareholders of record in January, February, and March 2025.

Summary of First Quarter 2025 Regular Monthly Dividends

Declared

Record Date

Payment Date

Amount per Share

1/9/2025

1/10/2025

1/31/2025

$0.12

1/9/2025

2/3/2025

2/28/2025

$0.12

1/9/2025

3/3/2025

3/31/2025

$0.12

About Stellus Private Credit BDC

The Company is an externally-managed, closed-end, non-diversified investment management company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing primarily in private middle-market companies (typically those with $5.0 million to $50.0 million of EBITDA (earnings before interest, taxes, depreciation and amortization)) through first lien (including unitranche) loans, second lien loans and unsecured debt financing, with corresponding equity co-investments. The Company’s investment activities are managed by its investment adviser, Stellus Private BDC Advisor, LLC.

Forward-Looking Statements

Statements included herein may contain “forward-looking statements” which relate to future performance or financial condition. Statements other than statements of historical facts included in this press release, including statements about COVID-19 and its impacts, may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of assumptions, risks and uncertainties, which change over time. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission including the final prospectus that will be filed with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Contacts
Stellus Private Credit BDC
W. Todd Huskinson, Chief Financial Officer
(713) 292-5414
thuskinson@stelluscapital.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/stellus-private-credit-bdc-announces-0-36-first-quarter-2025-regular-dividend-payable-monthly-in-increments-of-0-12-in-january-february-and-march-2025–302347311.html

SOURCE Stellus Private Credit BDC

Continue Reading

Technology

MongoDB, Inc. to Present at the 27th Annual Needham Growth Conference

Published

on

By

NEW YORK, Jan. 9, 2025 /PRNewswire/ — MongoDB, Inc. (NASDAQ: MDB) today announced that Chief Operating Officer and Chief Financial Officer, Michael Gordon, and Senior Vice President of Finance, Serge Tanjga, will present virtually at the 27th Annual Needham Growth Conference.

The MongoDB presentation is scheduled for Thursday, January 16, 2025, at 3:45 p.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the MongoDB investor relations website at https://investors.mongodb.com/news-events/events. A replay of the webcast will also be available for a limited time.

About MongoDB
Headquartered in New York, MongoDB’s mission is to empower innovators to create, transform, and disrupt industries by unleashing the power of software and data. Built by developers, for developers, MongoDB’s developer data platform is a database with an integrated set of related services that allow development teams to address the growing requirements for today’s wide variety of modern applications, all in a unified and consistent user experience. MongoDB has tens of thousands of customers in over 100 countries. The MongoDB database platform has been downloaded hundreds of millions of times since 2007, and there have been millions of builders trained through MongoDB University courses. To learn more, visit mongodb.com.

Investor Relations
Brian Denyeau
ICR for MongoDB
646-277-1251
ir@mongodb.com

Media Relations
MongoDB PR
press@mongodb.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mongodb-inc-to-present-at-the-27th-annual-needham-growth-conference-302347475.html

SOURCE MongoDB, Inc.

Continue Reading

Trending